Stock RGRX REGENERX BIOPHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News RegeneRx Biopharmaceuticals, Inc.

Equities

RGRX

US75886X3061

Market Closed - OTC Markets
Other stock markets
 11:28:37 2024-07-03 EDT 		5-day change 1st Jan Change
0.0014 USD 0.00% Intraday chart for RegeneRx Biopharmaceuticals, Inc. 0.00% +16.67%
2023 RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A. CI
2023 RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
RegeneRx Effects Reverse Stock Split and Terminates SEC Reporting Obligations
AQ
RegeneRx Receives Stockholder Approval for Reverse Stock Split
PR
RegeneRx Biopharmaceuticals : Submission of Matters to a Vote of Security Holders - Form 8-K
PU
RegeneRx To Extend Consent Solicitation Vote
PR
RegeneRx Biopharmaceuticals, Inc. announced that it has received $0.05 million in funding from Essetifin S.p.A.
CI
RegeneRx Biopharmaceuticals, Inc. announced that it expects to receive $0.175 million in funding
CI
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
RegeneRx Biopharmaceuticals, Inc. - First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical trial with RGN-259
AQ
First Patient Enrolled into U.S. Phase 3 Neurotrophic Keratitis Clinical Trial with RGN-259
PR
RegeneRx Issues Letter To Stockholders
PR
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operation. (form 10-K)
AQ
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
CI
Thymosin Beta 4 Research Leads Toward Potential Future Anti-Aging Therapy
CI
Thymosin Beta 4 Research Leads Toward Potential Future Anti-aging Therapy
PR
Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
PR
Regenerx Biopharmaceuticals, Inc. Reports New Scientific Publication of RGN-259 Phase 3 Clinical Trial Results in Patients with Neurotrophic Keratopathy
CI
REGENERX BIOPHARMACEUTICALS INC Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
AQ
RegeneRx Biopharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
RegeneRx Licensee Submits Special Protocol Assessment to FDA for 4th Phase 3 Clinical Trial for Dry Eye Disease
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RGRX Stock
  4. News RegeneRx Biopharmaceuticals, Inc.